{"title":"Advanced cell-derived drug delivery systems for pulmonary diseases: from bench to bedside.","authors":"Fei Li, Wenjie Xu, Junyong Wu, Jiwen Zhang, Xingyu Wei, Dehua Liao","doi":"10.1080/10717544.2025.2564814","DOIUrl":null,"url":null,"abstract":"<p><p>Nowadays, pulmonary diseases (PDs) are among the leading causes of mortality worldwide. Conventional therapeutic approaches exhibit disappointing efficacies due to difficulty in drug delivery and systemic cytotoxicity. In recent years, novel formulations of therapeutic drugs rised as alternatives for clinical treatment. Among them, cell-derived drug delivery systems (CDDSs) have garnered attention for their potential in treating PDs. By harnessing the innate migratory capabilities, barrier-crossing potential, high biocompatibility, and substantial drug-loading capacity of cell derivatives, CDDSs offer a promising approach for PD treatment. However, there was no systemic report in summarizing CDDSs in PDs. In this review, We first examined the biological properties and therapeutic advantages of various CDDSs in the context of PDs, including red blood cells (RBCs), stem cells, platelets, macrophages, neutrophils, tumor cells, microalgae, extracellular vesicles (EVs) and biomimetic cell membrane. We then discussed common preparation strategies and different modification methods of CDDSs. Finally, we summarized the current therapeutic advancements of CDDSs in multiple PDs. We hope this review serves as a valuable reference for utilizing CDDSs in the treatment of PDs and other diseases.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2564814"},"PeriodicalIF":8.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486461/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10717544.2025.2564814","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Nowadays, pulmonary diseases (PDs) are among the leading causes of mortality worldwide. Conventional therapeutic approaches exhibit disappointing efficacies due to difficulty in drug delivery and systemic cytotoxicity. In recent years, novel formulations of therapeutic drugs rised as alternatives for clinical treatment. Among them, cell-derived drug delivery systems (CDDSs) have garnered attention for their potential in treating PDs. By harnessing the innate migratory capabilities, barrier-crossing potential, high biocompatibility, and substantial drug-loading capacity of cell derivatives, CDDSs offer a promising approach for PD treatment. However, there was no systemic report in summarizing CDDSs in PDs. In this review, We first examined the biological properties and therapeutic advantages of various CDDSs in the context of PDs, including red blood cells (RBCs), stem cells, platelets, macrophages, neutrophils, tumor cells, microalgae, extracellular vesicles (EVs) and biomimetic cell membrane. We then discussed common preparation strategies and different modification methods of CDDSs. Finally, we summarized the current therapeutic advancements of CDDSs in multiple PDs. We hope this review serves as a valuable reference for utilizing CDDSs in the treatment of PDs and other diseases.
期刊介绍:
Drug Delivery is an open access journal serving the academic and industrial communities with peer reviewed coverage of basic research, development, and application principles of drug delivery and targeting at molecular, cellular, and higher levels. Topics covered include all delivery systems including oral, pulmonary, nasal, parenteral and transdermal, and modes of entry such as controlled release systems; microcapsules, liposomes, vesicles, and macromolecular conjugates; antibody targeting; protein/peptide delivery; DNA, oligonucleotide and siRNA delivery. Papers on drug dosage forms and their optimization will not be considered unless they directly relate to the original drug delivery issues. Published articles present original research and critical reviews.